نتایج جستجو برای: oxyntomodulin

تعداد نتایج: 147  

Journal: :Molecular pharmacology 2012
Francis S Willard Denise Wootten Aaron D Showalter Emilia E Savage James Ficorilli Thomas B Farb Krister Bokvist Jorge Alsina-Fernandez Sebastian G B Furness Arthur Christopoulos Patrick M Sexton Kyle W Sloop

Identifying novel mechanisms to enhance glucagon-like peptide-1 (GLP-1) receptor signaling may enable nascent medicinal chemistry strategies with the aim of developing new orally available therapeutic agents for the treatment of type 2 diabetes mellitus. Therefore, we tested the hypothesis that selectively modulating the low-affinity GLP-1 receptor agonist, oxyntomodulin, would improve the insu...

2010
Benjamin C.T. Field Alison M. Wren Veronique Peters Kevin C.R. Baynes Niamh M. Martin Michael Patterson Sara Alsaraf Vian Amber Katie Wynne Mohammad A. Ghatei Stephen R. Bloom

OBJECTIVE Peptide YY(3-36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal. Separately each hormone acts as an endogenous satiety signal and reduces appetite in humans when infused intravenously. The aim of the current study was to investigate whether the anorectic effects of PYY(3-36...

Journal: :The Journal of biological chemistry 1988
H G Pollock J W Hamilton J B Rouse K E Ebner A B Rawitch

Insulin, pancreatic polypeptide, glucagon, oxyntomodulin, and two distinct glucagon-like peptides were isolated from acidic ethanol extracts of bullfrog pancreas by gel filtration followed by high pressure liquid chromatography. The amino acid sequences of pancreatic polypeptide, oxyntomodulin, and both glucagon-like peptides were determined. Frog pancreatic polypeptide contains 36 amino acid r...

Journal: :Pancreas 2016
Elina Akalestou Ioannis Christakis Antonia M Solomou James S Minnion Guy A Rutter Stephen R Bloom

OBJECTIVES Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential antiobesity therapy, but little is known about its pancreatic safety. The aim of the study was to investigate the acute effect of oxyntomod...

Journal: :Clinical chemistry 2016
Anita Y H Lee Derek L Chappell Monika J Bak Michael Judo Linda Liang Tatyana Churakova Gulesi Ayanoglu Jose Castro-Perez Haihong Zhou Stephen Previs Sandra C Souza Michael E Lassman Omar F Laterza

BACKGROUND Proglucagon-derived peptides (PGDPs), which include glucagon-like peptide (GLP)-1, glucagon, and oxyntomodulin, are key regulators of glucose homeostasis and satiety. These peptide hormones are typically measured with immuno-based assays (e.g., ELISA, RIA), which often suffer from issues of selectivity. METHODS We developed a multiplexed assay for measuring PGDPs including GLP-1 (7...

Journal: :Diabetes 2005
Katie Wynne Adrian J Park Caroline J Small Michael Patterson Sandra M Ellis Kevin G Murphy Alison M Wren Gary S Frost Karim Meeran Mohammad A Ghatei Stephen R Bloom

This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain the...

Journal: :American journal of physiology. Gastrointestinal and liver physiology 2004
Sarah Stanley Katie Wynne Steve Bloom

Many peptides are synthesized and released from the gastrointestinal tract and pancreas, including pancreatic polypeptide (PP) and the products of the gastrointestinal L cells, glucagon-like peptide 1 (GLP-1), oxyntomodulin, and peptide YY (PYY). Whereas their roles in regulation of gastrointestinal function have been known for some time, it is now evident that they also influence eating behavi...

Journal: :The Journal of pharmacology and experimental therapeutics 2007
Rasmus Jorgensen Valentina Kubale Milka Vrecl Thue W Schwartz Christian E Elling

The glucagon-like peptide (GLP)-1 receptor is a promising target for the treatment of type 2 diabetes and obesity, and there is great interest in characterizing the pharmacology of the GLP-1 receptor and its ligands. In the present report, we have applied bioluminescence resonance energy transfer assays to measure agonist-induced recruitment of betaarrestins and G-protein-coupled receptor kinas...

2016
Nicolai J. Wewer Albrechtsen Daniel Hornburg Reidar Albrechtsen Berit Svendsen Signe Toräng Sara L. Jepsen Rune E. Kuhre Marie Hansen Charlotte Janus Andrea Floyd Asger Lund Tina Vilsbøll Filip K. Knop Henrik Vestergaard Carolyn F. Deacon Felix Meissner Matthias Mann Jens J. Holst Bolette Hartmann

Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating g...

2017
Sayali A Pendharkar Varsha M Asrani Rinki Murphy Richard Cutfield John A Windsor Maxim S Petrov

OBJECTIVES Diabetes has become an epidemic in developed and developing countries alike, with an increased demand for new efficacious treatments. A large body of pre-clinical evidence suggests that the gut-brain axis may be exploited as a potential therapeutic target for defective glucose homeostasis. This clinical study aimed to investigate a comprehensive panel of glucoregulatory peptides, rel...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید